Skip to main content

Table 1 Patients and disease characteristics

From: Pembrolizumab in combination with gemcitabine for patients with HER2-negative advanced breast cancer: GEICAM/2015–04 (PANGEA-Breast) study

Characteristics

N = 36

Age, years (median [range])

51 (31–77)

  < 65, n (%)

33 (91.7)

  ≥ 65, n (%)

3 (8.3)

Menopausal status, n (%)

 Postmenopausal

26 (72.2)

 Premenopausal

10 (27.8)

ECOG PS, n (%)

 0

23 (63.9)

 1

12 (33.3)

 2

1 (2.8)

Time since 1st BC diagnosis to study inclusion, years (median [range])

4 (1–37)

Time since M1 diagnosis to study inclusion, years (median [range])

2 (0.2–14)

Number of metastatic locations, n (%)

 1

9 (25.0)

 2

14 (38.9)

  ≥ 3

13 (36.2)

Metastatic locations, n (%)

 Visceral

28 (77.8)

  • Liver

25 (69.4)

  • Lung

7 (19.4)

  • Adrenal gland, pericardial effusion, or pleural involvement

6 (16.6)

 Non-visceral only

8 (22.2)

  • Bone

20 (55.6)

  • Breast

2 (5.6)

  • Lymph nodes

13 (36.1)

  • Skin

4 (11.1)

  • Soft tissue

5 (13.9)

Histological type, n (%)

 Invasive ductal carcinoma

33 (91.7)

 Invasive lobular carcinoma

2 (5.6)

 Invasive squamous carcinoma

1 (2.8)

Histological grade, n (%)

 1

1 (2.8)

 2

14 (38.9)

 3

16 (44.4)

 Unknown

5 (13.9)

HR status (local), n (%)

 Negative

21 (58.3)

 Positive

15 (41.7)

Ki67 expression (local) (%)

 Median (range)

30 (15–95)

  < 20%, n (%)

5 (13.9)

  ≥ 20%, n (%)

21 (58.3)

 Unknown

10 (27.8)

BC subtype by IHC (local), n (%)

 TN

21 (58.3)

 HR-positive disease

15 (41.7)

Prior therapy, n (%)

 CT

36 (100.0)

  • ABC

34 (94.4)

 ET

26 (72.2)

  • ABC

19 (52.8)

 BT

25 (69.4)

  • ABC

24 (66.7)

Number of prior lines for ABC, n (%)

 None

1 (2.8)

 1

9 (25.0)

 2

2 (5.6)

 3

3 (8.3)

 4

5 (13.9)

 5

7 (19.4)

  ≥ 6

9 (25.0)

 Median (range)

4 (0–11)

  • TN

2 (1–8)

  • HR-positive disease

5 (3–11)

  1. Abbreviations: n number of patients, ECOG PS Eastern Cooperative Oncology Group performance status, BC Breast cancer, M1 Metastases or metastatic disease, HR Hormone receptor, IHC Immunohistochemistry, TN Triple negative, CT Chemotherapy, ET Endocrine therapy, BT Biological therapy, ABC Advanced breast cancer